Kite, a Gilead Company, presented three analyses of Yescarta (axicabtagene ciloleucel) at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing improved outcomes for patients with relapsed or refractory large B-cell lymphomaB-cell lymphoma (R/R LBCL). The largest real-world evidence analysis to date confirmed high overall survival (OS) rates consistent with the ZUMA-7 trial, while separate data indicated a decreasing trend in cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS) incidence and severity. Additionally, the ALYCANTE study revealed stable or improved long-term quality of life for treated patients.
This news is highly significant for both Kite and the broader oncology field, as it validates the real-world effectiveness of Yescarta, a CAR T-cell therapy, in treating a challenging form of lymphoma. Demonstrating consistent positive outcomes in a larger and more diverse patient population than clinical trials reinforces the therapy’s potential to become a standard of care. The reduction in CRS and ICANS rates over time highlights the impact of increasing experience and refined treatment protocols in improving patient safety and managing treatment-related toxicities. This can lead to wider adoption of CAR T-cell therapies.
The largest real-world analysis, using data from the CIBMTR registry, included 446 patients and demonstrated a 71% OS rate at 12 months, aligning with the ZUMA-7 trial results. The analysis also revealed an overall response rate (ORR) of 79% and a complete response (CR) rate of 64%. Data from the same registry showed a significant decrease in Grade ≥ 3 CRS incidence in patients treated with Yescarta between 2022-2023 compared to 2017-2019. Similarly, both any-grade ICANS incidence and duration decreased over this period. The ALYCANTE study, focused on health-related quality of life (HRQoL), reported initial declines in some areas one month post-infusion, followed by stabilization or improvement at three and 12 months, respectively. These findings suggest that while some short-term adverse effects are observed, patients can experience long-term quality of life benefits.
These positive findings suggest a promising future for Yescarta and CAR T-cell therapy in R/R LBCL. The confirmation of efficacy and safety in real-world settings should bolster clinician confidence in using Yescarta earlier in the treatment course. The decreasing trend in CRS and ICANS, coupled with stable or improved HRQoL, further strengthens the therapy’s position as a valuable treatment option. Continued research and data collection will be vital to further refine treatment strategies and expand access to this potentially life-saving therapy for a wider range of patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
